Affordable Access

Publisher Website

Height, body mass index, and prostate cancer: a follow-up of 950 000 Norwegian men

Authors
Journal
British Journal of Cancer
0007-0920
Publisher
Nature Publishing Group
Publication Date
Identifiers
DOI: 10.1038/sj.bjc.6601206
Keywords
  • Epidemiology
Disciplines
  • Biology
  • Medicine

Abstract

Height, body mass index, and prostate cancer: a follow-up of 950 000 Norwegian men A Engeland*,1, S Tretli2 and T Bjørge3 1Division of Epidemiology, Norwegian Institute of Public Health, PO Box 4404 Nydalen, N-0403 Oslo, Norway; 2The Cancer Registry of Norway, Institute of population-based cancer research, N-0310 Oslo, Norway; 3Department of Pathology, The Norwegian Radium Hospital, N-0310 Oslo, Norway The present study explored body mass index (BMI), height, and risk of prostate cancer in a large Norwegian cohort of 950 000 men aged 20–74 years, whose height and weight were measured in a standardised way in the period 1963–1999. These were followed for an average of 21 years. The Cox proportional hazard models were used in the analyses. During follow-up, 33 300 histologically verified cases of prostate cancer were registered. The risk of prostate cancer increased by both BMI and height. The magnitude of the increase by BMI was modest, the relative risk (RR) of obese men (BMIX30) compared with normal weighted was 1.09 (95% CI: 1.04–1.15). However, the RR at age 50–59 years was 1.58 (95% CI: 1.29–1.94) in men being obese at about age 45 years compared with normal weighted men. The tallest men had an RR of 1.72 (95% CI: 1.46–2.04) compared with the shortest men. The overall effect of BMI on the incidence of prostate cancer was modest. The larger effect found in men aged 50–59 years might partly explain the previous inconsistent findings. British Journal of Cancer (2003) 89, 1237–1242. doi:10.1038/sj.bjc.6601206 www.bjcancer.com & 2003 Cancer Research UK Keywords: prostate cancer; cohort study; Norway � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � � Worldwide, prostate cancer is the third most common malignancy in men with an estimated number of 500 000 cases in the year 2000, three-quarters in men aged 65 years or older (Parkin et al, 2001). Around 1990, the incidence of prostate cancer increased in many countries due to the introduction of widespread bloo

There are no comments yet on this publication. Be the first to share your thoughts.